| DNTH |
Dianthus Therapeutics, Inc. /DE/ |
Common Stock, $0.001 par value |
9.9% |
$52.7M |
|
3.38M |
|
Avidity Partners Management LP |
Mar 17, 2025 |
| CNTX |
Context Therapeutics Inc. |
Common Stock, par value $0.001 per share |
9.9% |
$7.94M |
$1.17M |
9.13M |
+17.4% |
Avidity Partners Management LP |
Jun 30, 2025 |
| SCYX |
SCYNEXIS INC |
Common Stock, par value $0.001 per share |
9.9% |
$3.62M |
|
4.21M |
|
Avidity Master Fund LP |
Dec 31, 2024 |
| SYRS |
Syros Pharmaceuticals, Inc. |
Common Stock, $0.001 par value |
7.6% |
$41K |
|
2.05M |
|
Avidity Partners Management LP |
Dec 31, 2024 |
| KZR |
Kezar Life Sciences, Inc. |
Common Stock, par value $0.001 per share |
6.9% |
$387K |
|
503K |
|
Avidity Partners Management LP |
Dec 31, 2024 |
| IMUX |
IMMUNIC, INC. |
Common Stock, $0.0001 par value |
5.9% |
$4.77M |
-$361K |
5.62M |
-7.04% |
Avidity Partners Management LP |
Jun 30, 2025 |
| CATX |
Perspective Therapeutics, Inc. |
Common Stock, $0.001 par value |
4.2% |
$5.28M |
|
2.84M |
|
Avidity Partners Management LP |
Dec 31, 2024 |